Results 101 to 110 of about 4,742,503 (345)

Progestins and endometrial cancer

Gynecological Endocrinology, 2001
Premenopausal women--especially young women--with endometrial cancer stage I may be treated successfully with progestins alone as primary therapy to preserve their child-bearing potential. There is some indication that progestins could be used in neoadjuvant fashion.
openaire   +3 more sources

SF3A3 Drives Tumorigenesis in Endometrial Cancer by Enhancing c‐FOS Expression and Represents a Potential Therapeutic Target

Advanced Science, EarlyView.
The role of splicing factor 3A subunit 3 (SF3A3) in driving endometrial cancer (EC) progression and potential therapeutic interventions. SF3A3, a core component of the U2 small nuclear ribonucleoprotein (U2 snRNP), is upregulated in endometrial cancer (EC) and promotes tumor growth and cisplatin resistance. RNA‐binding protein immunoprecipitation (RIP)
Wei Yu, Yi Gu, Hengrui Zhang, Wunan Huang, Lei Sun, Liangjian Ma, Xiaolei Liang, Lexin Liu, Guiping Chen, Weihua Wang, Zhongkai Cao, Xue Li, Xiangjun Chen, Lidan Hu   +13 more
wiley   +1 more source

Mortalin and PINK1/Parkin‐Mediated Mitophagy Represent Ovarian Cancer‐Selective Targets for Drug Development

Advanced Science, EarlyView.
Ovarian cancer patients with high levels of mortalin protein in their tumors have worse survival. The investigational drug SHetA2 interferes with mortalin's support of mitochondria. The resulting mitochondrial damage causes a process called mitophagy that contributes to how SHetA2 kills cancer cells. Noncancerous cells repair their mitochondria through
Vishal Chandra, Justin Garland, Rajani Rai, Donghua Zhao, Charuksha Walgama, Sadagopan Krishnan, Andrew T. Long, Tongzu Liu, Laura Adhikari, Doris M. Benbrook   +9 more
wiley   +1 more source

Pelvic floor disorders in gynecological malignancies. An overlooked problem? [PDF]

, 2018
Cervical, endometrial, ovarian, vulvar, and vaginal cancers affect women of a broad age spectrum. Many of these women are still sexually active when their cancer is diagnosed.
Bodean, Oana M., Cirstoiu, Monica, Diaconu, Camelia C., Marcu, Radu D., Munteanu, Octavian, Socea, Bogdan, Spinu, Dan A., Taus, Nicoleta   +7 more
core   +3 more sources

EETs Reduction Contributes to Granulosa Cell Senescence and Endometriosis‐Associated Infertility via the PI3K/AKT/mTOR Signaling Pathway

Advanced Science, EarlyView.
1) 14, 15‐EET levels were decreased in ovarian granulosa cells, follicular fluid, peritoneal fluid from endometriosis patients. 2) EETs reduction in endometriosis follicular fluid aggravated granulosa cell senescence. 3) ROS reduced 14, 15‐EET levels by upregulating EPHX2 through a mechanism involving histone methylation modification.
Xiang Lin, Weijia Gu, Xiaomei Tong, Mengru Lai, Yi Zhang, Na Liu, Xiaoying Jin, Chao Li, Dong Huang, Feng Zhou, Yongdong Dai, Songying Zhang   +11 more
wiley   +1 more source

WTAP Mediated m6A Modification Stabilizes PDIA3P1 and Promotes Tumor Progression Driven by Histone Lactylation in Esophageal Squamous Cell Carcinoma

Advanced Science, EarlyView.
This study reveals a new mechanism by which PDIA3P1 regulates the progression of esophageal squamous cell carcinoma (ESCC). PDIA3P1 upregulates the expression of GLUT1 and HK2, promoting glycolysis and lactate production. Lactate upregulates the lactylation level of histone H4K8 and activates the transcription of target gene BMP7, ultimately ...
Tao Huang, Qi You, Jiawei Liu, Xuguang Shen, Dengjun Huang, Xinlu Tao, Zhijie He, Chengwei Wu, Xinran Xi, Shouqiang Yu, Feng Liu, Zhihao Wu, Wenjun Mao, Shaojin Zhu   +13 more
wiley   +1 more source

Lenvatinib Plus Paclitaxel as Second‐Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study

Advanced Science, EarlyView.
This study determines the maximum tolerated dose of lenvatinib in combination with paclitaxel as second‐line therapy for advanced gastric cancer patients. A dynamic network biomarker panel associated with patient prognosis and response to treatment is established.
Chenfei Zhou, Jinling Jiang, Liting Guo, Wenqi Xi, Junwei Wu, Qu Cai, Jun Ji, Feng Qi, Jun Zhang   +8 more
wiley   +1 more source

Comparison of Risk Factors and survival of Type 1 and Type II Endometrial Cancers [PDF]

, 1969
Tahira Y Malik, Uzma Chishti, Aliya Begum Aziz, Sheikh Irfan   +3 more
openalex   +1 more source

Incorporation of molecular characteristics into endometrial cancer management

Histopathology, 2019
Histopathological evaluation including subtyping and grading is the current cornerstone for endometrial cancer (EC) classification. This provides clinicians with prognostic information and input for further treatment recommendations.
L. Vermij, V. Smit, R. Nout, T. Bosse
semanticscholar   +1 more source

Surgery for Older Cancer Patients: Cross‐Organ Review and Good Practice Statement by the Japanese Geriatric Oncology Guideline Committee

Annals of Gastroenterological Surgery, EarlyView.
We conducted a cross‐organ review of surgical outcomes in older cancer patients based on literature cited in Japanese clinical guidelines. This study summarizes postoperative complication rates and survival outcomes across five major cancer types. The findings aim to support the development of geriatric oncology surgical guidelines tailored to Japan's ...
Chie Tanaka, Takashi Ofuchi, Kiichiro Ninomiya, Daisuke Inoue, Ken Sugimoto, Keiko Murofushi, Toru Okuyama, Shigeaki Watanuki, Chiyo Imamura, Daisuke Sakai, Naomi Sakurai, Kiyotaka Watanabe, Kazuo Tamura, Toshiaki Saeki, Hiroshi Ishiguro   +14 more
wiley   +1 more source